Close Menu

In Science Signaling this week, researchers in the UK say amplification of oncogenes KRAS or BRAF underpins an acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. The researchers modeled acquired resistance to the MEK 1/2 inhibitor selumetinib in colorectal cancer cells with BRAF or KRAS mutations. Genomic sequencing showed no acquired mutations in MEK1 or MEK2, selumetinib's primary targets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.